https://1investing.in/ Modulation Technologies Inc. is focused on development and commercialization of a novel implantable SNM system for patients with urinary and bowel dysfunction and disrupting the SNM market. Axonics Modulation Technologies Inc. is based in Irvine, CA. The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction. Live educational sessions using site features to explore today’s markets. Maintaining independence and editorial freedom is essential to our mission of empowering investor success.
These are established companies that reliably pay dividends. The Barchart Technical Opinion widget shows you today’s overally Barchart Opinion with general information on how to interpret the short and longer term signals. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating.
Revenue and Earnings Metrics
Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. 8 equities research analysts have issued 12 month price objectives for Axonics’ shares. Their AXNX share price forecasts range from $71.00 to $90.00. On average, they predict the company’s stock price to reach $78.63 in the next year. This suggests a possible upside of 36.8% from the stock’s current price.
MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Bilibili’s fourth-quarter 2022 results are likely to reflect strength in mobile gaming revenues. However, increasing channel and marketing expenses are expected to have kept margins under pressure….
Specifically, they have bought $0.00 in company stock and sold $5,778,945.00 in company stock. Axonics has received a 59.34% net impact score from Upright. The largest positive contribution comes from its “Physical diseases” impact, which is driven by its “Incontinence medication”, “Implants and prostheses”, and “Medical technology engineering” products. Axonics does not have a long track record of dividend growth.
Axonics Modulation Technologies Inc. priced its initial public offering at $15 a share, the midpoint of its $14 to $16 price range. The medical technology company, which specializes in sacral neuromodulation treatments fo… We are sitting on an unrealized return of 3.0% on Carpenter Technology from the buy write on February 14. The company reports earnings tomorrow and I’d like to lock in those profits by selling the stock today. Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends.
An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy. Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares.
Right-click on the chart to open the Interactive Chart menu. For US and Canadian Stocks, the Overview page includes key statistics on the stock’s fundamentals, with a link to see more. Provides a general description of the business conducted by this company. Barchart is committed to ensuring digital accessibility for individuals with disabilities.
Benzinga’s Top Ratings Upgrades, Downgrades For April 14, 2023
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated. Two stocks that were making their debut on Wednesday were lower in afternoon trade, failing to benefit from the overall market’s sharp gains. Shares of Orchard Therapeutics Plc , a biotech that specializes in ex vivo gene …
- It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally.
- Real-time quotes, advanced visualizations, backtesting, and much more.
- Medical technology company Axonics Modulation Technologies Inc. set terms for its planned initial public offering on Monday, saying it will offer 6.7 million shares priced at $14 to $16 each.
- Morningstar Quantitative ratings for equities are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
- The company’s average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.
We play several thematics in this space, one being centred around urinary incontinence. Specifically, we are long several names making breakthrough’s in the prostate surgery domain and have see… Raised $100 million in an IPO on Wednesday, October 31st 2018.
There may be delays, omissions, or inaccuracies in the Information. The industry with the best average Zacks Rank would be considered the top industry , which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank would place in the bottom 1%.
This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies. The company’s average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings. Fulgent Genetics, Inc. delivered earnings and revenue surprises of 14.29% and 13.90%, respectively, for the quarter ended December 2022. Shares Sold ShortThe total number of shares of a security that have been sold short and not yet repurchased.Change from LastPercentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.Percent of FloatTotal short positions relative to the number of shares available to trade.
17 best prepaid debit cards with no fees, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation devices to treat patients with bladder and bowel dysfunction. Its product Bulkamid, which is a urethral bulking agent used to treat stress urinary incontinence in women. The company was founded by Raymond W. Cohen, Guang Qiang Jiang, and Danny L. Dearen in March 2012 and is headquartered in Irvine, CA. High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks.
AXNX shares are trading higher after the company reported preliminary fourth-quarter and full-year 2022 total net revenue results above estimates. We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers. 20 employees have rated Axonics Chief Executive Officer Raymond W. Cohen on Glassdoor.com. Raymond W. Cohen has an approval rating of 89% among the company’s employees. 73.0% of employees surveyed would recommend working at Axonics to a friend. The company is scheduled to release its next quarterly earnings announcement on Monday, May 1st 2023.
We are continuously working to improve our web experience, and encourage users to Contact Us for feedback and accommodation requests. Take your analysis to the next level with our full suite of features, known and used by millions throughout the trading world. Axnx bull flaggonna watch out for this one, earnings catalyst should push this higher. Gonna watch out for this one, earnings catalyst should push this higher.
Now, even Taiwan’s own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself. 3 people have searched for AXNX on MarketBeat in the last 30 days. MarketBeat has tracked 10 news articles for Axonics this week, compared to 3 articles on an average week.
CompareAXNX’s historical performanceagainst its industry peers and the overall market. Our Quantitative Research team models direct competitors or comparable companies from a bottom-up perspective to find companies describing their business in a similar fashion. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Below are the latest news stories about AXONICS INC that investors may wish to consider to help them evaluate AXNX as an investment opportunity. We have 9 different ratings for every stock to help you appreciate its future potential. By creating a free account, you agree to our terms of service.